Monday

September 15

17:00 - 17:15

Opening / welcome

17:15 - 18:00

Keynote speaker Andreas Bjerrum, Copenhagen University Hospital, Denmark
Putting data to work for precision oncology - Experiences from Capital Region of Denmark (40 + 5 min)

19:00 - 21:30

Get together / Mingling buffet

Tuesday

September 16

09.00 - 09.45

Keynote Speaker Edwin Cuppen, Hartwig Medical Foundation
Routine whole genome sequencing-based cancer diagnostics for precisionmedicine and research (40 + 5 min)

9:45 - 10:15

Coffee Break

Session 1: Precision Diagnostics

Chair: Hege G. Russnes

10:15 - 10:45

Alona Sosinsky, Genomics England

Integrating whole genome sequencing into clinical practice for cancer patients (25 + 5 min)

10:45 - 11:00

Gang Chen, University of Melbourne

Cost-effectiveness of circulating tumour-derived methylated DNA markers for stage II colon cancer prognostication post-resection (10 + 5 min)

11:00 - 11:30

Janne Lehtiö, Karolinska Institutet

Title (25 + 5 min)

11:30 - 11:45

Bjarne Johannessen, Oslo University Hospital

Developing a molecular classifier independent of intra-patient heterogeneity in primary prostate cancer (10 + 5 min)

11:45 - 12:15

Kushtrim Kryeziu, Oslo University Hospital

Functional precision oncology in practice: lessons from the EVIDENT trial (25 + 5 min)

12:15 - 13:00

Poster Session, Part 1

13:00 - 14:00

Lunch

14:00 - 15:00

Poster Session, Part 2

14:45 - 15:10

Coffee Break

Session 2: Precision immune oncology & Functional Precision Oncology

Chair: Kjetil Taskén

15:00 - 15:30

Diana Azzam, Florida International University

Functional Precision Medicine to GuideIndividualized Cancer Treatment (25 + 5 min)

15:30 - 15:45

Alfonso Urbanucci, Oslo University Hospital & Tampere University

A cancer vaccine for de novo metastatic prostate cancer: learning from the UV1 trial (10 + 5 min)

15:45 - 16:15

Coffee Break

16:15 - 16:45

Thorsten Zenz, Univeristy Hospital Zurich

Leveraging drug perturbation of primary lymphoma cells for precision cancer care (25 + 5 min)

16:45 - 17:00

Pilar Ayuda-Durán, Oslo University Hospital

Impact of treatment sequence on synergistic and antagonistic drug interactions in melanoma (10 + 5 min)

17:00 - 17:30

Heidi Haikala, University of Helsinki

Studying personalized antitumor immune responses using fully human model systems (25 + 5 min)

19:15

Aperitif

20:00

Dinner

Wednesday

September 17

9:00 - 9:45

Keynote Speaker Patricia LoRusso
Yale Cancer Center
Title (40 + 5 min)

9:45 - 10:15

Coffee Break

Session 3A: Precision Cancer Medicine Trials

Chair: Åslaug Helland

10:15 - 10:45

Anna Martling, Karolinska Institutet

Low-Dose Aspirin for Secondary Prevention in Colorectal Cancer: Results from the Nordic ALASCCA Trial — A 50% Reduction in Recurrence in Genetically Selected Patients (25 + 5 min)

10:45 - 11:00

Sheraz Yaqub, Oslo University Hospital

Aspirin as secondary prevention for colorectal cancer liver metastases (ASAC): A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial (10 + 5 min)

11:00 - 11:30

Ruth Plummer, Newcastle University & Newcastle Hospitals NHS Foundation Trust, UK

Bench to Bedside for new Cancer Treatments – experience of academic drug discovery (25 + 5 min)

11:30 - 12:30

Lunch

Session 3B: PCM Trials

Chair: TBD

12:30 - 12:45

Katarina Puco, Oslo University Hospital

Improving access to clinical trials for patients with rare cancers: experiences from the IMPRESS-Norway trial (10 + 5 min)

12:45 - 13:15

Kimmo Porkka, Helsinki University Hospital

Functional tumor profiling and harmonized data networks for implementing precision cancer care (25 + 5 min)

Session 4: PCM Implementation

Chair: Live Fagereng

13:15 - 13:45

Christine Leopold, Utrecht Center for Pharmaceutical Policy and Regulation

Life cycle management of precision medicine: the case of managed entry agreements (25 + 5 min)

13:45 - 14:00

Bettina Ryll, Stockholm School of Economics Institute for Research

Recommendations for the equitable implementation of precision cancer medicine in Europe - learnings from the PCM4EU consortium (10 + 5 min)

14:00 - 14:25

Coffee Break

14:25 - 14:55

David Thomson, National Inst. for Health and Care Excellence (NICE), UK

Trends in pricing and reimbursement of PCM drugs (25 + 5 min)

14:55 - 15:10

Oskar Frisell, The Swedish Institute for Health Economics

A conceptual health economic modelling framework to assess the cost-effectiveness of molecular target driven treatment regimens in oncology (10 + 5 min)

15:10 - 15:40

Per-Olof Thuresson, Roche

Title (25 + 5 min)

15:40 - 15:50

Concluding Remarks

Nordic Precision Cancer Medicine

An Acta Oncologica Conference

The overarching theme of this two-day conference is precision cancer medicine. Internationally renowned speakers will give scientific updates as well as updates on collaborative initiatives and implementation of precision cancer medicine across the Nordics and other European countries.

NPCM 2025

An Acta Oncologica Conference

Pages:

Home
Program
Topics
Speakers
Abstract
Practical